These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 728284)

  • 41. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disopyramide plasmakinetics and pharmacodynamics applied to the assessment of bioavailability [proceedings].
    Bryson SM; Lawrence JR; Whiting B
    Br J Clin Pharmacol; 1977 Oct; 4(5):633P. PubMed ID: 911618
    [No Abstract]   [Full Text] [Related]  

  • 43. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haemodynamic effects of disopyramide using a new model of intravenous administration.
    Bonde J; Pedersen LE; Angelo HR; Svendsen TL; Trap-Jensen J; Graudal NA; Kampmann JP
    Pharmacol Toxicol; 1987 Mar; 60(3):179-83. PubMed ID: 3588512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative high-performance liquid-chromatographic method for determining disopyramide (Norpace) in serum.
    Broussard LA; Frings CS
    Clin Toxicol; 1979; 14(5):579-86. PubMed ID: 498727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The renal clearance of disopyramide after bolus intravenous injection.
    Lawrence JR; Bryson SM; Sumner DJ; Campbell BC; Whiting B
    Biopharm Drug Dispos; 1979; 1(2):51-7. PubMed ID: 552861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent use of quinidine and disopyramide: evaluation of serum concentrations and electrocardiographic effects.
    Baker BJ; Gammill J; Massengill J; Schubert E; Karin A; Doherty JE
    Am Heart J; 1983 Jan; 105(1):12-5. PubMed ID: 6849225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.
    Wiesel FA; Alfredsson G; Ehrnebo M; Sedvall G
    Eur J Clin Pharmacol; 1980 May; 17(5):385-91. PubMed ID: 7418717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
    Ward JW; Kinghorn GR
    J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
    [No Abstract]   [Full Text] [Related]  

  • 51. Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.
    Ranney RE; Dean RR; Karim A; Radzialowski FM
    Arch Int Pharmacodyn Ther; 1971 May; 191(1):162-88. PubMed ID: 4104224
    [No Abstract]   [Full Text] [Related]  

  • 52. Disopyramide plasma and myocardial tissue concentrations as they relate to antiarrhythmic activity.
    Patterson E; Stetson P; Lucchesi BR
    J Cardiovasc Pharmacol; 1979; 1(5):541-50. PubMed ID: 94410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum disopyramide concentrations and suppression of ventricular premature contractions.
    Ueda CT; Dzindzio BS; Vosik WM
    Clin Pharmacol Ther; 1984 Sep; 36(3):326-36. PubMed ID: 6467792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacokinetic study of disopyramide in normal man].
    Mallein R; Rondelet J; Boucherat M; Ksavrelof M; Pignat M
    Therapie; 1978; 33(4):463-73. PubMed ID: 734626
    [No Abstract]   [Full Text] [Related]  

  • 56. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 58. Disopyramide in renal impairment.
    Whiting B; Elliott HL
    Lancet; 1977 Dec 24-31; 2(8052-8053):1363. PubMed ID: 74774
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.
    Hinderling PH; Garrett ER
    J Pharmacokinet Biopharm; 1976 Jun; 4(3):199-230. PubMed ID: 978389
    [No Abstract]   [Full Text] [Related]  

  • 60. Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease.
    Bonde J; Pedersen LE; Angelo HR; Trap-Jensen J; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 30(2):161-6. PubMed ID: 3709640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.